Feb 2021 – The output from SELENA+ Deep Learning System (DLS) was assessed and has been finally accepted by Discovery Health, the leading medical scheme administrator in South Africa for reimbursement under the Chronic Illness Benefit for Diabetes Mellitus. Under this scheme, beneficiaries who use SELENA+ for a diabetic retinopathy screening are entitled to reimbursement on receipt of a referral report.

This breakthrough is set to revolutionise retinal disease screening in the country, where SELENA+ can make screening faster, cheaper and more consistent. This is especially crucial because South Africa has a high prevalence of diabetics in the population. South Africa is one of the 47 countries of the International Diabetes Federation (IDF) Africa region. According to IDF’s latest statistics, 463 million people have diabetes in the world and more than 19 million people in the Africa Region; by 2045 this will rise to 47 million. South Africa has a population of 58.56 million and a diabetic prevalence of 12.7%.

With this recognition, EyRIS hopes to make eye screening more accessible to the population in South Africa and eventually the rest of the continent; with the ultimate aim of reducing preventable vision impairment.


About Discovery Health

Discovery Health is the largest medical scheme administrator in South Africa, providing administration and managed care services to over 3.3 million beneficiaries. The business has a market share of over 40% in the overall medical scheme market in South Africa, and manages 18 restricted medical schemes on behalf of leading corporate clients, as well as Discovery Health Medical Scheme, South Africa’s largest open medical scheme.


Please direct all queries related to this article to Marketing at

Comments are closed.